# PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma

> **NCT02615730** · PHASE1,PHASE2 · COMPLETED · sponsor: **Yonsei University** · enrollment: 42 (actual)

## Conditions studied

- Advanced Gastric Adenocarcinoma

## Interventions

- **DRUG:** GSK2636771
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT02615730
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02
- **Primary completion:** 2021-03-31
- **Final completion:** 2021-03-31
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02615730

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02615730, "PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02615730. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*